Disease Trajectories Before ESRD: Implications for Clinical Management

Seminars in Nephrology

Volumn 37, Issue 2, 2017, Pages 132-143

  Sumida, Keiichi ^a   Kovesdy, Csaba P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; end stage renal disease; estimated glomerular filtration rate; heterogeneity; trajectory

Indexed keywords

CREATININE;

ARTERIOVENOUS FISTULA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; CLINICAL OUTCOME; CLINICAL PRACTICE; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DISEASE ASSESSMENT; DISEASE COURSE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; INCIDENCE; MORTALITY RISK; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; RENAL REPLACEMENT THERAPY; REVIEW; VASCULAR ACCESS; ARTERIOVENOUS SHUNT; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY;

ARTERIOVENOUS SHUNT, SURGICAL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PALLIATIVE CARE; RENAL DIALYSIS;

EID: 85011973259     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2016.12.003     Document Type: Review

References (81)

1. 1 Saran, R., Li, Y., Robinson, B., Abbott, K.C., Agodoa, L.Y., Ayanian, J., et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 67:Suppl 1 (2016), A7–A8.
2. 2 Eckardt, K.U., Coresh, J., Devuyst, O., Johnson, R.J., Kottgen, A., Levey, A.S., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382 (2013), 158–169.
3. 3 Robinson, B.M., Zhang, J., Morgenstern, H., Bradbury, B.D., Ng, L.J., McCullough, K.P., et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 85 (2014), 158–165.
4. 4 Keane, W.F., Zhang, Z., Lyle, P.A., Cooper, M.E., de Zeeuw, D., Grunfeld, J.P., et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 1 (2006), 761–767.
5. 5 Keith, D.S., Nichols, G.A., Gullion, C.M., Brown, J.B., Smith, D.H., Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004), 659–663.
6. 6 Levin, A., Djurdjev, O., On being better kidney doctors: understanding trajectories, probabilities, predictability, and people. Am J Kidney Dis 59 (2012), 475–477.
7. 7 Mitch, W.E., Walser, M., Buffington, G.A., Lemann, J. Jr., A simple method of estimating progression of chronic renal failure. Lancet 2 (1976), 1326–1328.
8. 8 Coresh, J., Turin, T.C., Matsushita, K., Sang, Y., Ballew, S.H., Appel, L.J., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311 (2014), 2518–2531.
9. 9 Kovesdy, C.P., Coresh, J., Ballew, S.H., Woodward, M., Levin, A., Naimark, D.M., et al. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol 27 (2016), 2447–2455.
10. 10 Turin, T.C., Jun, M., James, M.T., Tonelli, M., Coresh, J., Manns, B.J., et al. Magnitude of rate of change in kidney function and future risk of cardiovascular events. Int J Cardiol 202 (2016), 657–665.
11. 11 Murtagh, F.E., Murphy, E., Sheerin, N.S., Illness trajectories: an important concept in the management of kidney failure. Nephrol Dial Transplant 23 (2008), 3746–3748.
12. 12 Rosansky, S., Early dialysis initiation and renal function trajectory. J Intern Med 269 (2011), 275–277.
13. 13 Wong, S.P., Vig, E.K., Taylor, J.S., Burrows, N.R., Liu, C.F., Williams, D.E., et al. Timing of initiation of maintenance dialysis: a qualitative analysis of the electronic medical records of a national cohort of patients from the Department of Veterans Affairs. JAMA Intern Med 176 (2016), 228–235.
14. 14 Jensen, A.B., Moseley, P.L., Oprea, T.I., Ellesoe, S.G., Eriksson, R., Schmock, H., et al. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun, 5, 2014, 4022.
15. 15 Lunney, J.R., Lynn, J., Foley, D.J., Lipson, S., Guralnik, J.M., Patterns of functional decline at the end of life. JAMA 289 (2003), 2387–2392.
16. 16 Teno, J.M., Weitzen, S., Fennell, M.L., Mor, V., Dying trajectory in the last year of life: does cancer trajectory fit other diseases?. J Palliat Med 4 (2001), 457–464.
17. 17 Murray, S.A., Kendall, M., Boyd, K., Sheikh, A., Illness trajectories and palliative care. BMJ 330 (2005), 1007–1011.
18. 18 Johnson, E.S., Thorp, M.L., Platt, R.W., Smith, D.H., Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am J Kidney Dis 52 (2008), 653–660.
19. 19 Fox, C.S., Matsushita, K., Woodward, M., Bilo, H.J., Chalmers, J., Heerspink, H.J., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380 (2012), 1662–1673.
20. 20 Mahmoodi, B.K., Matsushita, K., Woodward, M., Blankestijn, P.J., Cirillo, M., Ohkubo, T., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 380 (2012), 1649–1661.
21. 21 Derose, S.F., Rutkowski, M.P., Crooks, P.W., Shi, J.M., Wang, J.Q., Kalantar-Zadeh, K., et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis 62 (2013), 236–244.
22. 22 Freedman, B.I., Parekh, R.S., Kao, W.H., Genetic basis of nondiabetic end-stage renal disease. Semin Nephrol 30 (2010), 101–110.
23. 23 Murtagh, F.E., Marsh, J.E., Donohoe, P., Ekbal, N.J., Sheerin, N.S., Harris, F.E., Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 22 (2007), 1955–1962.
24. 24 Murtagh, F.E., Sheerin, N.S., Addington-Hall, J., Higginson, I.J., Trajectories of illness in stage 5 chronic kidney disease: a longitudinal study of patient symptoms and concerns in the last year of life. Clin J Am Soc Nephrol 6 (2011), 1580–1590.
25. 25 Davison, S.N., Simpson, C., Hope and advance care planning in patients with end stage renal disease: qualitative interview study. BMJ, 333, 2006, 886.
26. 26 Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
27. 27 Levey, A.S., Measurement of renal function in chronic renal disease. Kidney Int 38 (1990), 167–184.
28. 28 Hunsicker, L.G., Adler, S., Caggiula, A., England, B.K., Greene, T., Kusek, J.W., et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51 (1997), 1908–1919.
29. 29 Rosansky, S.J., Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. Am J Nephrol 36 (2012), 1–10.
30. 30 Boucquemont, J., Heinze, G., Jager, K.J., Oberbauer, R., Leffondre, K., Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art. BMC Nephrol, 15, 2014, 45.
31. 31 Li, L., Astor, B.C., Lewis, J., Hu, B., Appel, L.J., Lipkowitz, M.S., et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 59 (2012), 504–512.
32. 32 OʼHare, A.M., Batten, A., Burrows, N.R., Pavkov, M.E., Taylor, L., Gupta, I., et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis 59 (2012), 513–522.
33. 33 Kovesdy, C.P., Anderson, J.E., Derose, S.F., Kalantar-Zadeh, K., Outcomes associated with race in males with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 4 (2009), 973–978.
34. 34 Leffondre, K., Boucquemont, J., Tripepi, G., Stel, V.S., Heinze, G., Dunkler, D., Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrol Dial Transplant 30 (2015), 1237–1243.
35. 35 Hemmelgarn, B.R., Zhang, J., Manns, B.J., Tonelli, M., Larsen, E., Ghali, W.A., et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 69 (2006), 2155–2161.
36. 36 Turin, T.C., Coresh, J., Tonelli, M., Stevens, P.E., de Jong, P.E., Farmer, C.K., et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant 27 (2012), 3835–3843.
37. 37 Xie, D., Joffe, M.M., Brunelli, S.M., Beck, G., Chertow, G.M., Fink, J.C., et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol 3 (2008), 1332–1338.
38. 38 Rifkin, D.E., Shlipak, M.G., Katz, R., Fried, L.F., Siscovick, D., Chonchol, M., et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168 (2008), 2212–2218.
39. 39 Al-Aly, Z., Zeringue, A., Fu, J., Rauchman, M.I., McDonald, J.R., El-Achkar, T.M., et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol 21 (2010), 1961–1969.
40. 40 Matsushita, K., Selvin, E., Bash, L.D., Franceschini, N., Astor, B.C., Coresh, J., Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20 (2009), 2617–2624.
41. 41 Manjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D.N., Griffith, J.L., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 (2003), 47–55.
42. 42 Shlipak, M.G., Katz, R., Kestenbaum, B., Siscovick, D., Fried, L., Newman, A., et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 20 (2009), 2625–2630.
43. 43 Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003), 2154–2169.
44. 44 Kottgen, A., Russell, S.D., Loehr, L.R., Crainiceanu, C.M., Rosamond, W.D., Chang, P.P., et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18 (2007), 1307–1315.
45. 45 Odden, M.C., Chertow, G.M., Fried, L.F., Newman, A.B., Connelly, S., Angleman, S., et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition Study. Am J Epidemiol 164 (2006), 1180–1189.
46. 46 Lambers Heerspink, H.J., Weldegiorgis, M., Inker, L.A., Gansevoort, R., Parving, H.H., Dwyer, J.P., et al. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 63 (2014), 244–250.
47. 47 Turin, T.C., Coresh, J., Tonelli, M., Stevens, P.E., de Jong, P.E., Farmer, C.K., et al. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int 83 (2013), 684–691.
48. 48 Osborn, T.M., Dahlgren, C., Hartwig, J.H., Stossel, T.P., Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 292 (2007), C1323–C1330.
49. 49 Lee, P.S., Waxman, A.B., Cotich, K.L., Chung, S.W., Perrella, M.A., Stossel, T.P., Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 35 (2007), 849–855.
50. 50 Lee, P.S., Sampath, K., Karumanchi, S.A., Tamez, H., Bhan, I., Isakova, T., et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 20 (2009), 1140–1148.
51. 51 Hsu, R.K., Chai, B., Roy, J.A., Anderson, A.H., Bansal, N., Feldman, H.I., et al. Abrupt decline in kidney function before initiating hemodialysis and all-cause mortality: the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 68 (2016), 193–202.
52. 52 Sumida, K., Molnar, M.Z., Potukuchi, P.K., Thomas, F., Lu, J.L., Jing, J., et al. Association of slopes of estimated glomerular filtration rate with post-end-stage renal disease mortality in patients with advanced chronic kidney disease transitioning to dialysis. Mayo Clin Proc 91 (2016), 196–207.
53. 53 Ku, E., Xie, D., Shlipak, M., Hyre, Anderson A., Chen, J., Go, A.S., et al. Change in measured GFR versus eGFR and CKD outcomes. J Am Soc Nephrol 27 (2016), 2196–2204.
54. 54 Abra, G., Kurella, Tamura M., Timing of initiation of dialysis: time for a new direction?. Curr Opin Nephrol Hypertens 21 (2012), 329–333.
55. 55 Yu, M.K., OʼHare, A.M., Batten, A., Sulc, C.A., Neely, E.L., Liu, C.F., et al. Trends in timing of dialysis initiation within versus outside the Department of Veterans Affairs. Clin J Am Soc Nephrol 10 (2015), 1418–1427.
56. 56 OʼHare, A.M., Wong, S.P., Yu, M.K., Wynar, B., Perkins, M., Liu, C.F., et al. Trends in the timing and clinical context of maintenance dialysis initiation. J Am Soc Nephrol 26 (2015), 1975–1981.
57. 57 Schell, J.O., Patel, U.D., Steinhauser, K.E., Ammarell, N., Tulsky, J.A., Discussions of the kidney disease trajectory by elderly patients and nephrologists: a qualitative study. Am J Kidney Dis 59 (2012), 495–503.
58. 58 Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 48:Suppl 1 (2006), S248–S273.
59. 59 Pisoni, R.L., Arrington, C.J., Albert, J.M., Ethier, J., Kimata, N., Krishnan, M., et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 53 (2009), 475–491.
60. 60 Polkinghorne, K.R., Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 15 (2004), 477–486.
61. 61 Wasse, H., Kutner, N., Zhang, R., Huang, Y., Association of initial hemodialysis vascular access with patient-reported health status and quality of life. Clin J Am Soc Nephrol 2 (2007), 708–714.
62. 62 Lacson, E. Jr, Wang, W., DeVries, C., Leste, K., Hakim, R.M., Lazarus, M., et al. Effects of a nationwide predialysis educational program on modality choice, vascular access, and patient outcomes. Am J Kidney Dis 58 (2011), 235–242.
63. 63 Lacson, E. Jr, Wang, W., Lazarus, J.M., Hakim, R.M., Change in vascular access and hospitalization risk in long-term hemodialysis patients. Clin J Am Soc Nephrol 5 (2010), 1996–2003.
64. 64 Bradbury, B.D., Chen, F., Furniss, A., Pisoni, R.L., Keen, M., Mapes, D., et al. Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis 53 (2009), 804–814.
65. 65 OʼHare, A.M., Bertenthal, D., Walter, L.C., Garg, A.X., Covinsky, K., Kaufman, J.S., et al. When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration?. Kidney Int 71 (2007), 555–561.
66. 66 Hiremath, S., Knoll, G., Weinstein, M.C., Should the arteriovenous fistula be created before starting dialysis?: a decision analytic approach. PLoS One, 6, 2011, e28453.
67. 67 Korsheed, S., Eldehni, M.T., John, S.G., Fluck, R.J., McIntyre, C.W., Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 26 (2011), 3296–3302.
68. 68 Golper, T.A., Hartle, P.M., Bian, A., Arteriovenous fistula creation may slow estimated glomerular filtration rate trajectory. Nephrol Dial Transplant 30 (2015), 2014–2018.
69. 69 Locatelli, F., Zoccali, C., Arteriovenous fistula as a nephroprotective intervention in advanced CKD: scientific discovery and explanation, and the evaluation of interventions. Nephrol Dial Transplant 30 (2015), 1939–1941.
70. 70 Sumida, K., Molnar, M.Z., Potukuchi, P.K., Thomas, F., Lu, J.L., Ravel, V.A., et al. Association between vascular access creation and deceleration of estimated glomerular filtration rate decline in late-stage chronic kidney disease patients transitioning to end-stage renal disease. Nephrol Dial Transplant, 2016 pii: gfw220 [Epub ahead of print].
71. 71 OʼHare, A.M., Choi, A.I., Boscardin, W.J., Clinton, W.L., Zawadzki, I., Hebert, P.L., et al. Trends in timing of initiation of chronic dialysis in the United States. Arch Intern Med 171 (2011), 1663–1669.
72. 72 Kurella, M., Covinsky, K.E., Collins, A.J., Chertow, G.M., Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 146 (2007), 177–183.
73. 73 Wachterman, M.W., Marcantonio, E.R., Davis, R.B., Cohen, R.A., Waikar, S.S., Phillips, R.S., et al. Relationship between the prognostic expectations of seriously ill patients undergoing hemodialysis and their nephrologists. JAMA Intern Med 173 (2013), 1206–1214.
74. 74 Treit, K., Lam, D., OʼHare, A.M., Timing of dialysis initiation in the geriatric population: toward a patient-centered approach. Semin Dial 26 (2013), 682–689.
75. 75 Brunori, G., Treatment of chronic kidney disease in the elderly: diet or conservative management. J Nephrol 25:Suppl 19 (2012), S28–S31.
76. 76 Tinetti, M.E., Fried, T., The end of the disease era. Am J Med 116 (2004), 179–185.
77. 77 Burns, A., Conservative management of end-stage renal failure: masterly inactivity or benign neglect? See Smith et al., pp. c40-c46. Nephron Clin Pract 95 (2003), c37–c39.
78. 78 Noble, H., Chesser, A., Kelly, D., The cessation of dialysis in patients with end-stage renal disease: developing an appropriate evidence base for practice. EDTNA ERCA J 31 (2005), 208–211.
79. 79 Murtagh, F.E., Addington-Hall, J.M., Donohoe, P., Higginson, I.J., Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J 32 (2006), 93–98.
80. 80 Murphy, E.L., Murtagh, F.E., Carey, I., Sheerin, N.S., Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract 111 (2009), c74–c80.
81. 81 Carson, R.C., Juszczak, M., Davenport, A., Burns, A., Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease?. Clin J Am Soc Nephrol 4 (2009), 1611–1619.